These findings [71], and those of others [55,69,70,76], suggest that if a targeted disruption of Gal-1 expression/function in tumor tissue or the immediate tumor microenvironment could be obtained, it may be a plausible therapeutic option for cisplatin-resistant ovarian cancer. The gene discussed is LGALS1; the disease is ovarian carcinoma.